Abiopharma

🔍 Veradace Partners LP (Executive)

Company: SOUNDTHINKING, INC. (SSTI)

Report Date: 2026-03-20

Detailed Transactions and Holdings:

• Acquired 50,000 shares of SOUNDTHINKING,INC. at $7.5 per share (Direct)
  Date: 2026-03-20 | Code: M | equity_swap_involved: 0 | shares_owned_after: 2,089,805.00 | transaction_form_type: 4
• Sold 50,000 shares of SOUNDTHINKING,INC. at $7.5 per share (Derivative)
  Date: 2026-03-20 | Code: M | Expires: 2026-03-20 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1

Footnotes:

• F1: The option was exercisable at any time prior to expiration. The reporting person was assigned on previously written put options that were automatically exercised by the broker in accordance with their terms. The reported price reflects the strike price.
• REMARKS: 1. This Form 4 is being filed by Veradace Partners, LP, a Delaware limited partnership ("Veradace Partners" or the "Fund") and Veradace Capital Management, LLC, a Delaware limited liability company ("Veradace Capital Management"), investment manager to the Fund.2. The price reported for each transaction in this table reflects the weighted average price of multiple same‑day transactions. On each day, the prices of the executed transactions did not vary more than a dollar. These transactions were reported on an aggregate basis pursuant to the No‑Action Letter Regarding Aggregate Reporting under Section 16(a) of the Securities Exchange Act of 1934, issued on June 25, 2008 by the Division of Corporation Finance of the Securities and Exchange Commission. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, more than $1. 3. The reporting person is an investment manager that directly holds the securities reported herein. Certain affiliated entities and individuals, by virtue of their control of the reporting person, may be deemed to share beneficial ownership of such securities for purposes of Section 16 of the Securities Exchange Act of 1934. An amendment to this Form 3 will be filed to include such additional reporting persons once the necessary EDGAR access credentials have been obtained. Each such person disclaims beneficial ownership of the reported securities except to the extent of his or its pecuniary interest therein.